| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Peptides | Endocrine System | ||
phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Peptides | Endocrine System | ||
phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Peptides | Endocrine System |
Recent Updates
Recently added Catalysts
Opko Health Inc.$1.21
+0.01 (+0.42%)
B 77Pipeline Score Undervalued Biotech · Commercial
Market Cap
880.52 M
EPS
-0.30
P/E Ratio
-3.84 $
Value Trade
6.78 M
SEC Financials
Q1 2026Dilution Risk
Revenue
124.20 M
R&D Expenses
29.20 M
Operating CF
-19.31 M
Total Assets
1.86 B
Total Liabilities
652.19 M
Equity
1.20 B
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
331.86 M
Monthly Burn
6.44 M
Runway
49.1 mo
Burn Trend
SEC Filing
Apr 28, 2026
Overview
Volume
2.18 M
52 Week Range
1.10 - 1.60
% held by Insiders
50.65 %
% held by Institutions
28.3 %
Enterprise Value
908.23 M
Total Shares
758.89 M
Short %
8.75 %
Float Shares
330.12 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Opko Health Inc.
218Total events
4Upcoming
70Tier-1 (high impact)
2016 – 2027Coverage
Upcoming catalysts 2
TBD
T2Quarterly Update
Subscribe to view catalyst details
TBD
T2IND Submission
Subscribe to view catalyst details
Event history 2
TBD
●Quarterly UpdateCorporate
Subscribe to view catalyst details
TBD
◆Poster PresentationOPK8801001Presentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2025-09-13 | Oral GLP-2 Analog | Pre-clinical data readout | Pre-clinical | — | – | – | – |
2025-09-13 | Oral GLP-2 Analog | Pre-clinical data readout | Pre-clinical | — | – | – | – |
2025-09-13 | Oral GLP-2 Analog | Pre-clinical data readout | Pre-clinical | — | – | – | – |
Drug Pipeline Intelligence
B77
Pipeline Score $13.2B
Pipeline ValueUndervalued
Valuation Signal22
Drugs Scored15.0x
rNPV / MCap Top 97%
Micro Cap (rank 28 of 912)
Percentile RankOpko Health Inc. holds a solid B-grade pipeline (77/100), with $52.3B risk-adjusted pipeline value, led by CTAP101 30 μg in Chronic Kidney Disease (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CTAP101 30 μg Small molecule | Chronic Kidney Disease | Phase 3 | NCT01704079 | 60% | $14.7B | COMPLETED | 429 | - | - | Sep 1, 2014 | - | Jan 13, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
OPK-88006 | metabolic dysfunction-associated steatohepatitis (MASH) | — | 2025-07-31 | the therapeutic benefits of OPK-88006 on quantitative biological hallmarks of MASH were superior to semaglutide and survodutide Read More | OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI Read More | |
OPK-88006 | metabolic dysfunction-associated steatohepatitis (MASH) | — | 2025-07-31 | the therapeutic benefits of OPK-88006 on quantitative biological hallmarks of MASH were superior to semaglutide and survodutide Read More | OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI Read More | |
OPK-88006 | metabolic dysfunction-associated steatohepatitis (MASH) | — | 2025-07-31 | the therapeutic benefits of OPK-88006 on quantitative biological hallmarks of MASH were superior to semaglutide and survodutide Read More | OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in OPK
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
OPK Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-OPK
Jun 15, 2026Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026
OPKO Biologics presented promising preclinical data for OPK8801001 at ENDO 2026, indicating its potential as a long-acting treatment for acromegaly. The data demonstrated significant suppression of IGF-1 levels, suggesting a weekly dosing alternative to current daily therapies. The findings reinforce OPKO's commitment to developing innovative treatment options for patients with endocrine disorders.
Read more →-OPK
Apr 30, 2026BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform
BioReference Health LLC has launched BioReference Direct, a digital platform that allows consumers to access laboratory testing directly. This initiative aims to enhance patient-driven healthcare by providing a seamless online experience for selecting tests. The platform includes various health panels and an at-home STI test in collaboration with Abbott, promoting early detection and proactive health management.
Read more →-OPK
Apr 29, 2026▼ -8.3%on this newsshared move
OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results
OPKO Health, Inc. reported its business highlights and financial results for the first quarter of 2026. The company reaffirmed its financial guidance for the year and scheduled a conference call to discuss these results. However, the report included cautionary forward-looking statements regarding product development and regulatory challenges.
Read more →-OPK
Feb 27, 2026OPKO Health to Participate in the Jefferies Biotech on the Beach Summit
OPKO Health, Inc. will participate in the Jefferies Biotech on the Beach Summit on March 10-11, 2026, at 1 Hotel South Beach in Miami. The company plans to hold one-on-one meetings with registered investors on March 11. This engagement aims to strengthen investor relations and showcase OPKO's biopharmaceutical and diagnostics expertise.
Read more →-OPK
Feb 26, 2026OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI
OPKO Health, Inc. has reported its fourth-quarter business highlights and financial results for 2025, showcasing a collaboration with Regeneron Pharmaceuticals estimated to exceed $1 billion in potential value. The company announced advancements in clinical trials for novel cancer treatments MDX2003 and MDX2004, while also presenting an increase in revenue from product sales. However, total consolidated revenues have decreased, attributed to prior asset sales, along with a rise in operating losses when compared to the same quarter last year.
Read more →-OPK
Feb 12, 2026OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26
OPKO Health, Inc. plans to report its financial results for Q4 2025 on February 26, 2026. The announcement includes a conference call where senior management will discuss the results and provide financial guidance. Participants can pre-register for easier access to the call, which will also be available via webcast.
Read more →-OPK
Feb 4, 2026OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism
OPKO Health and Entera Bio have expanded their partnership to develop a first-in-class oral long-acting PTH tablet for hypoparathyroidism. The companies plan to file an IND application with the FDA in late 2026, following promising preclinical data. This collaboration aims to provide a more convenient treatment option for patients, moving away from daily injections.
Read more →-OPK
Oct 29, 2025OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI
OPKO Health, Inc. reported their third quarter 2025 business highlights and financial results, including significant developments such as a partnership with Regeneron Pharmaceuticals to develop multispecific antibodies. The sale of BioReference Health clinical assets for $225 million is expected to enhance OPKO's financial stability. While total revenues declined compared to the previous year, the company made strides in advancing its oncology and vaccine programs, showcasing its commitment to innovation in the health sector.
Read more →-OPK
Sep 15, 2025Labcorp Completes Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses BURLINGTON, N.C. and MIAMI
Labcorp has completed the acquisition of select assets from BioReference Health, a subsidiary of OPKO Health, enhancing its oncology clinical testing services. The deal, valued at up to $225 million, aims to provide expanded access to quality laboratory services across the U.S. Through this acquisition, Labcorp is committed to improving cancer care. OPKO Health plans to focus on its core clinical testing operations and intends to use part of the proceeds for share repurchase.
Read more →-OPK
Jul 31, 2025OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI
OPKO Health, Inc. reported its second-quarter financial results and business highlights for 2025. The company noted advancements in its vaccine trials in collaboration with Merck and the development of its novel drug OPK-88006, which demonstrated promising data for treating metabolic diseases. The FDA approved the 4KScore Test, enhancing its use in cancer assessments. However, OPKO experienced a decline in revenue and an increased net loss compared to the previous year, primarily due to significant non-recurring expenses.
Read more →-OPK
Mar 8, 2023▲ +6.6%on this news
Document OPKO Health's ModeX Therapeutics Enters into Exclusive Worldwide License and Collaboration Agreement with Merck to Develop Epstein-Barr Virus Vaccine Candidate MDX-2201 leverages ModeX's innovative biologics pla
OPKO Health's ModeX Therapeutics has entered an exclusive worldwide license and collaboration agreement with Merck to develop MDX-2201, a nanoparticle vaccine targeting Epstein-Barr virus (EBV). This collaboration is marked by an upfront payment of $50 million, with potential milestone payments up to $872.5 million. MDX-2201 employs ModeX's innovative multitargeting approach to target multiple EBV proteins, aiming to improve protective immunity. The partnership leverages both companies' strengths in vaccine development to tackle a critical health issue associated with EBV infections.
Read more →-OPK
Feb 23, 2023▲ +5.7%on this news
Document OPKO Health Reports Fourth Quarter 2022 Business Highlights and Financial Results Conference call begins at 4 30 p.m. Eastern time today MIAMI (
OPKO Health, Inc. released its fourth quarter 2022 financial results, revealing a revenue of $185.4 million compared to $401.3 million in the previous year. The company saw an increase in pharmaceutical revenue driven by products like RAYALDEE, despite a notable decline in diagnostics revenue due to reduced COVID-19 testing. The firm reported an operating loss of $55.3 million, reflecting higher costs and expenses, while a $2.5 million revenue was recognized from Nicoya. OPKO's management will provide an update and discuss these results during a conference call today.
Read more →-OPK
Nov 8, 2022Document OPKO Health Reports Third Quarter 2022 Business Highlights and Financial Results Conference call begins at 4 30 p.m. Eastern time today MIAMI (
OPKO Health Reports Third Quarter 2022 Business Highlights and Financial Results Conference call begins at 4 30 p.m. Eastern time today MIAMI (November 8, 2022) - OPKO Health, Inc. (NASDAQ OPK) reports business highlights and financial results for the three months ended Septemb
Read more →-OPK
Aug 4, 2022Document OPKO Health Reports 2022 Second Quarter Business Highlights and Financial Results Conference call begins at 4 30 p.m. Eastern time today MIAMI (
OPKO Health Reports 2022 Second Quarter Business Highlights and Financial Results Conference call begins at 4 30 p.m. Eastern time today MIAMI (August 4, 2022) - OPKO Health, Inc. (NASDAQ OPK) reports business highlights and financial results for the three and six months ended
Read more →-OPK
May 9, 2022▼ -6.9%on this news
Document OPKO Health Reports 2022 First Quarter Business Highlights and Financial Results Conference call begins at 4 30 p.m. Eastern time today MIAMI (
OPKO Health Reports 2022 First Quarter Business Highlights and Financial Results Conference call begins at 4 30 p.m. Eastern time today MIAMI (May 9, 2022) - OPKO Health, Inc. (NASDAQ OPK) reports business highlights and financial results for the three months ended March 31, 20
Read more →-OPK
Feb 24, 2022▲ +8.4%on this news
Document OPKO Health Reports 2021 Fourth Quarter Business Highlights and Financial Results Conference call begins at 4 30 p.m. Eastern time today MIAMI (
OPKO Health Reports 2021 Fourth Quarter Business Highlights and Financial Results Conference call begins at 4 30 p.m. Eastern time today MIAMI (February 24, 2022) - OPKO Health, Inc. (NASDAQ OPK) reports business highlights and financial results for the three months ended Decem
Read more →-OPK
Oct 28, 2021Document OPKO Health Reports 2021 Third Quarter Business Highlights and Financial Results Conference call begins at 4 30 p.m. Eastern time today MIAMI (
OPKO Health Reports 2021 Third Quarter Business Highlights and Financial Results Conference call begins at 4 30 p.m. Eastern time today MIAMI (October 28, 2021) - OPKO Health, Inc. (NASDAQ OPK) reports business highlights and financial results for the three months ended Septemb
Read more →-OPK
Feb 18, 2021Document OPKO Health Reports 2020 Fourth Quarter Business Highlights and Financial Results Conference call begins at 4 30 p.m. Eastern time today MIAMI (
OPKO Health Reports 2020 Fourth Quarter Business Highlights and Financial Results Conference call begins at 4 30 p.m. Eastern time today MIAMI (February 18, 2021) - OPKO Health, Inc. (NASDAQ OPK) reports business highlights and financial results for the three months ended Decem
Read more →-OPK
Jan 13, 202113x21 January 2021 NASDAQ: OPK January 2021 | 2 This presentation contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be
January 2021 NASDAQ: OPK January 2021 | 2 This presentation contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "wil
Read more →-OPK
Oct 29, 2020Document OPKO Health Reports 2020 Third Quarter Business Highlights and Financial Results Conference call begins at 4 30 p.m. Eastern time today MIAMI (
OPKO Health Reports 2020 Third Quarter Business Highlights and Financial Results Conference call begins at 4 30 p.m. Eastern time today MIAMI (October 29, 2020) - OPKO Health, Inc. (NASDAQ OPK) reports business highlights and financial results for the three months ended Septemb
Read more →-OPK
Jul 30, 2020OPKO Health Reports 2020 Second Quarter Business Highlights and Financial Results
OPKO Health Reports 2020 Second Quarter Business Highlights and Financial Results Conference call begins at 4:45 p.m. Eastern time today MIAMI (July 30, 2020) - OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended June 30,
Read more →-OPK
May 6, 2020OPKO Health Reports 2020 First Quarter Business Highlights and Financial Results
OPKO Health Reports 2020 First Quarter Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI (May 6, 2020) - OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2
Read more →-OPK
Feb 26, 2020OPKO Health Reports 2019 Fourth Quarter Business Highlights and Financial Results
OPKO Health Reports 2019 Fourth Quarter Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI (February 26, 2020) - OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended Dece
Read more →-OPK
Nov 5, 2019OPKO Health Reports 2019 Third Quarter Business Highlights and Financial Results
OPKO Health Reports 2019 Third Quarter Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI (November 5, 2019) - OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended Septem
Read more →-OPK
Sep 23, 2019a8khghctpex991 Long-Term Safety of a Once-Weekly Somatrogon (hGH-CTP): 4-Year Results of a Phase 2 Extension Study in Children with Growth Hormone Deficiency Nataliya Zelinska1, Yulia Skorodok2, Oleg Malievsky3, Violeta
Long-Term Safety of a Once-Weekly Somatrogon (hGH-CTP): 4-Year Results of a Phase 2 Extension Study in Children with Growth Hormone Deficiency Nataliya Zelinska1, Yulia Skorodok2, Oleg Malievsky3, Violeta Iotova4, Ron G. Rosenfeld5, Zvi Zadik6, Shelly Vander7, and Aleksandra Past
Read more →-OPK
Aug 7, 2019OPKO Health Reports 2019 Second Quarter Business Highlights and Financial Results
OPKO Health Reports 2019 Second Quarter Business Highlights and Financial Results Conference call begins today at 4:30 p.m. Eastern time MIAMI (August 7, 2019) - OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended June 30
Read more →-OPK
May 7, 2019OPKO Health Reports 2019 First Quarter Business Highlights and Financial Results
OPKO Health Reports 2019 First Quarter Business Highlights and Financial Results Conference call begins today at 4:30 p.m. Eastern time MIAMI (May 7, 2019) - OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2
Read more →-OPK
Feb 27, 2019OPKO Health Reports 2018 Fourth Quarter Business Highlights and Financial Results
OPKO Health Reports 2018 Fourth Quarter Business Highlights and Financial Results Conference Call begins today at 4:30 p.m. Eastern Time MIAMI (February 27, 2019) - OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended Dece
Read more →-OPK
Jan 29, 2019and our consolidated financial statements and the related notes thereto. Effective
Page Part II. Item 6. Selected Financial Data 2 Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 3 Item 7A. Quantitative and Qualitative Disclosures about Market Risk 27 Item 8. Financial Statements and Supplementary Data 28 Part IV
Read more →-OPK
Dec 27, 2018OPKO Health and OPKO s CEO and Chairman, Dr.
OPKO Health and OPKO s CEO and Chairman, Dr. Phillip Frost, Announce Proposed Resolution of SEC Action Frost to continue as CEO and Chairman of Opko MIAMI ( PR NEWSWIRE) Dec. 27, 2018 In a settlement, subject to court approval, OPKO Health, Inc. (NASDAQ: OPK) and OPKO s CEO an
Read more →-OPK
Nov 9, 2018OPKO Health Reports Third Quarter 2018 Financial Results Conference Call begins today at 4:15 p.m. Eastern Time MIAMI (
OPKO Health Reports Third Quarter 2018 Financial Results Conference Call begins today at 4:15 p.m. Eastern Time MIAMI (November 9, 2018) - OPKO Health, Inc. (NASDAQ: OPK) reports financial results and business highlights for the three months ended September 30, 2018. Financial
Read more →-OPK
Aug 7, 2018Lippert Heilshorn & Associates
Lippert Heilshorn & Associates Moderator: Miriam Miller 08-07-18/4:30 p.m. ET Confirmation # 9243717 Lippert Heilshorn & Associates Moderator: Miriam Miller To ask a question, please press star followed by one on your touchtone telephone. As a reminder, this conference is b
Read more →-OPK
Aug 7, 2018OPKO Health Reports Second Quarter 2018 Financial Results
OPKO Health Reports Second Quarter 2018 Financial Results Conference Call begins today at 4:30 p.m. Eastern Time MIAMI (August 7, 2018) - OPKO Health, Inc. (NASDAQ: OPK) reports financial results and business highlights for the three months ended June 30, 2018. Financial Highl
Read more →-OPK
Jun 6, 2018Forward Looking Statements This presentation contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words
June 2018 Exhibit 99.1 Forward Looking Statements This presentation contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "proje
Read more →-OPK
Mar 1, 2018Client Id: 77 THOMSON REUTERS STREETEVENTS PRELIMINARY TRANSCRIPT OPK Q4 2017 OPKO Health Inc Earnings Call EVENT DATE/TIME: MARCH 01, 2018 / 9:30PM GMT THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us 20
Client Id: 77 THOMSON REUTERS STREETEVENTS PRELIMINARY TRANSCRIPT OPK Q4 2017 OPKO Health Inc Earnings Call EVENT DATE/TIME: MARCH without the prior written consent of Thomson Reuters. Thomson Reuters and the Thomson Reuters logo are registered trademarks of Thomson Reuters and
Read more →-OPK
Nov 8, 2017THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us 2017 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited
NOVEMBER 08, 2017 / 9:30PM, OPK - Q3 2017 OPKO Health Inc Earnings Call CORPORATE PARTICIPANTS Health, Inc. - CFO, CAO, SVP and Treasurer Anne Marie Fields Lippert/Heilshorn & Associates, Inc. - SVP David Okrongly Opko Health, Inc. - President of OPKO Diagnostics Philip Fros
Read more →-OPK
Nov 8, 2017OPKO Health Reports 2017 Third Quarter Highlights and Financial Results RAYALDEE total prescriptions increased 66% in Q3 2017 compared with Q2 2017 4Kscore utilization increased 19% in Q3 2017 compared with Q3 2016 4Ksco
OPKO Health Reports 2017 Third Quarter Highlights and Financial Results MIAMI (November 8, 2017) OPKO Health, Inc. (NASDAQ:OPK), reports operating and financial results for the three months ended September 30, 2017. Financial Highlights CONFERENCE CALL & WEBCAST INFORMATION:
Read more →-OPK
Oct 12, 2017OPKO Health Enters into Exclusive Agreement with Japan Tobacco to Develop and Commercialize RAYALDEE in Japan OPKO to receive up to $118 million in upfront and milestone payments, plus tiered double-digit royalties on pr
OPKO Health Enters into Exclusive Agreement with Japan Tobacco to Develop and Commercialize RAYALDEE in Japan OPKO to receive up to $118 million in upfront and milestone payments, plus tiered double-digit royalties on product sales MIAMI (October 12, 2017) OPKO Health, Inc. (
Read more →-OPK
Sep 7, 2017FORWARD-LOOKING statementS This presentation contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words
September 2017 NASDAQ: OPK Diagnostics & Pharmaceuticals for Large Markets with Unmet Needs Exhibit 99.1 FORWARD-LOOKING statementS This presentation contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLR
Read more →-OPK
Jun 15, 2017This presentation contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans,"
Opko health, Inc. Annual shareholders meeting June 15, 2017 Exhibit 99.1 This presentation contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "ex
Read more →-OPK
Jan 1, 2017Diagnostics & Pharmaceuticals for Large Markets with Unmet Needs January 2017 NASDAQ: OPK FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements, as that term is defined under the Private Securi
Diagnostics & Pharmaceuticals for Large Markets with Unmet Needs January 2017 NASDAQ: OPK FORWARD-LOOKING STATEMENTS contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identif
Read more →-OPK
Nov 7, 2016OPKO Health Reports Financial Third Quarter Operating Results Consolidated revenue increased to $298.0 million for the three months ended
OPKO Health Reports Financial Third Quarter Operating Results MIAMI (November 7, 2016) OPKO Health, Inc. (NASDAQ:OPK), reports financial and operating results for the three months ended September 30, 2016. Financial Highlights We are finalizing the details of our commercial l
Read more →-OPK
Aug 31, 2016OPKO Health Completes Acquisition of Transition Therapeutics MIAMI (
OPKO Health Completes Acquisition of Transition Therapeutics MIAMI (August 31, 2016) OPKO Health, Inc. (NASDAQ: OPK), announces that it has completed its previously announced acquisition of Transition Therapeutics, Inc. (NASDAQ: TTHI, TSX: TTH), by way of a plan of arrangement
Read more →-OPK
Aug 8, 2016OPKO Health Reports Improved Financial and Operating Results Net income was $15.5 million and $3.6 million for the three and six months ended
OPKO Health Reports Improved Financial and Operating Results MIAMI (August 8, 2016) OPKO Health, Inc. (NYSE:OPK), reports financial and operating results for the three and six months ended June 30, Financial Highlights Our improved financial performance this quarter was fueled
Read more →Competitive Position
How OPK ranks across every disease it competes inCompetitive Position is a premium feature
See how OPK ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial